Medical imaging services specialist IXICO Plc (LON:IXI) has signed a new contract with a top 10 pharmaceutical company that is an existing client.
The contract value is £1.0mlm over a three-year term, with study planning and site set-up activities starting in the next few months, IXICO said.
WATCH: IXICO sees strong topline growth in interim results
IXICO will provide its technology-enabled imaging services in a natural history study of people with early manifest Huntington's disease to observe the natural progression of the disease.
IXICO will use its TrialTracker digital platform to standardise the acquisition and collection of magnetic resonance imaging (MRI) scans, including advanced functional MR imaging, from centres across Europe and North America. IXICO will also apply its proprietary image analysis algorithms, together with in-licensed algorithms from leading academic centres, to measure neurological changes in study participants.
"Today's announcement continues IXICO's successful track record in providing neuroimaging clinical trial services for Huntington's disease, representing our third new contract in this therapeutic area in the current financial year,” said Giulio Cerroni, the chief executive officer of IXICO.
“I am delighted that we continue to win new business with existing clients which I believe demonstrates the value placed by our customers on the unique combination of technologies and scientific expertise that we provide," he added.